GU Cancers 2021 | TERTp mutations as prognostic markers in urothelial cancer
Vadim Koshkin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of TERT promoter (TERTp) mutations as prognostic markers in patients with advanced urothelial carcinoma who have received treatment with immune checkpoint inhibitors (ICIs). Reliable prognostic factors are lacking for locally advanced or metastatic urothelial cancer (aUC). A retrospective analysis of 78 patients with aUC who had previously been treated with ICIs found that the presence of a TERTp mutation was an independent predictor of overall survival in patients with aUC who are treated with ICIs. This interview took place during the 2021 Genitourinary Cancers Symposium.
Disclosures
Vadim Koshkin, MD, has served in a consulting or advisory role for AstraZeneca, Clovis, Janssen, Pfizer, EMD Serono, Seattle Genetics/Astellas and Dendreon; has received institutional research funding from Endocyte, Nektar, Clovis, Janssen and Taiho; and has received grant funding from the Prostate Cancer Foundation.
